Introduction
============

Lung adenocarcinoma (LUAD) is the most predominant subtype of non-small cell lung cancer (NSCLC), with increased incidence over the past decades worldwide ([@b1-ol-0-0-10931],[@b2-ol-0-0-10931]). LUAD is usually observed in the peripheral region of the lungs, with a poor overall five-year survival rate of 15% worldwide in 2008 ([@b3-ol-0-0-10931]). Due to resistance to radiation therapy, LUAD is often treated surgically ([@b4-ol-0-0-10931]). Nonetheless, approximately a third of patients relapse within five years of surgical removal ([@b5-ol-0-0-10931]).

DNA methylation, a primary epigenetic modification in the mammalian genome, often occurs at CpG islands, leading to altered tumor suppressor gene transcription ([@b6-ol-0-0-10931]). Aberrant DNA methylation plays a key role in the progression and metastasis of LUAD, reflecting important biological features in the etiology ([@b7-ol-0-0-10931]). Zhu *et al* ([@b8-ol-0-0-10931]) identified a group of genes with differentially methylated loci in LUAD. Han *et al* ([@b9-ol-0-0-10931]) found that methylated *PTPRF* (protein tyrosine phosphatase, receptor type F), *HOXD3* (homeobox D 3), *HOXD13* and *CACNA1A* (calcium voltage-gated channel subunit alpha1 A) may be potential markers of LUAD, based on DNA methylation profiling analysis. Furthermore, Sandoval *et al* ([@b10-ol-0-0-10931]) suggested a prognostic signature based on five hypermethylated genes for early stage NSCLC. Additionally, Kuo *et al* ([@b11-ol-0-0-10931]) established a proof-of-concept prognostic signature of eight methylated probes for survival prediction in Asian and Caucasian populations with early-stage LUAD. Despite these remarkable findings, there is a lack of a prognostic DNA methylation signature for LUAD.

In the present study, genome-wide methylation analysis was carried out on the methylation data of 425 patients with LUAD, with corresponding clinicopathological features from The Cancer Genome Atlas (TCGA). LUAD-associated co-methylation modules were mined with the weighted correlation network analysis (WGCNA) package. Furthermore, a group of differentially methylated genes (DMGs) predictive of survival were identified for LUAD by performing differential DNA methylation, correlation, univariate Cox regression and L1 penalized (LASSO) Cox proportional hazards (PH) regression analyses. These findings may potentially contribute to a deeper insight into the epigenetic landscape of LUAD and improve the prognostic evaluation of patients.

Materials and methods
=====================

### Data resources

DNA methylation data and the corresponding survival information of 425 LUAD tissue samples were downloaded from TCGA portal (<https://gdc-portal.nci.nih.gov/>) on May 26th, 2018, based on the Illumina Infinium Human Methylation 450 BeadChip platform, and were used as the training set in the present study. The GSE39279 dataset was downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>), based on the Illumina Infinium Human Methylation 450 BeadChip platform, consisting of the gene methylation data of 443 NSCLC samples. Among these samples, 155 LUAD samples with available survival information were selected as the validation set. The clinicopathological features of the training set and the validation set are shown in [Table I](#tI-ol-0-0-10931){ref-type="table"}.

### Differential DNA methylation analysis

A bad prognosis was defined as patients who died or who had a survival time \<12 months, whereas a good prognosis indicated living patients who survived \>24 months. According to the annotation profiles provided by the platform, only the DNA methylation loci in CpGs were reserved. The comparison of samples associated with good and bad prognosis from the TCGA set, identified differentially methylated CpGs (DM CpGs), using the limma package ([@b12-ol-0-0-10931]) of R language (version 3.34.7; <http://bioconductor.org/packages/release/bioc/html/limma.html>). A strict cut-off value was set at false discovery rate (FDR)\<0.05 and \|Log~2~fold change (FC)\|\>0.1. The genes mapped by the identified DM CpGs were defined as the DMGs.

### Co-methylation analysis

In order to analyze the inter-correlation among the identified DM CpGs, co-methylation network analysis was carried out using the WGCNA R package (version 1.63; <http://cran.r-project.org/web/packages/WGCNA/index.html>), as previously described ([@b13-ol-0-0-10931]). Briefly, a thresholding power function (β) of 5 was chosen to fit a scale-free network. Topological overlap matrix (TOM) was then calculated to measure the correlations between the methylation levels of two genes. The resulting hierarchical clustering dendrogram was obtained, followed by selection of the modules with a minimum module size of 100 and a minimum cut height of 0.95, using the Dynamic Tree Cut algorithm. These identified DM CpGs were then mapped to the modules obtained by WGCNA analysis. The enrichment of target DM CpGs in each module was assessed by hypergeometric-based test ([@b14-ol-0-0-10931]), using the following formula: f (k, N, M, n) = C (k, M) × C (n-k, N-M)/C (n, N).

The modules with P\<0.05 and fold enrichment \>1 were further selected as LUAD-associated modules and subjected to Gene ontology (GO) enrichment analysis using the DAVID 6.8 software ([@b15-ol-0-0-10931],[@b16-ol-0-0-10931]). This revealed the biological functions of the DMGs clustered in these modules.

### Correlation of DNA methylation level with gene expression level

The genome-wide expression data of the LUAD samples in the TCGA set was obtained. The correlation between the overall methylation level and the overall gene expression level of the DMGs, included in the LUAD-associated modules, was analyzed with the cor.test function of R language by calculating the Pearson\'s correlation coefficient (PCC) ([@b17-ol-0-0-10931]). Subsequently, the PCC of the overall methylation level of each individual gene, with its overall gene expression level was also computed. The genes with negative PCC and P\<0.05 were used for further analysis.

### Construction of a prognostic risk scoring model based on the training set

Univariate Cox regression analysis was performed to identify the prognosis-associated DMGs from the aforementioned genes with negative PCC, using the survival package of R language ([@b18-ol-0-0-10931]) (<http://bioconductor.org/packages/survivalr/>), with log-rank P\<0.05 as the cutoff.

A LASSO estimation-based Cox-PH model ([@b19-ol-0-0-10931]) was used to select the optimal panel of genes predictive of prognosis from these prognosis-related DMGs by the penalized package (version 0.9--50) ([@b20-ol-0-0-10931]) of R language. Combining the Cox-PH coefficients of the optimal genes with their methylation levels, a risk scoring model was constructed for predicting survival as follows: Risk score = ∑ coef~gene~ × methylation~gene~, where coef~gene~ represents the Cox-PH coefficient of a gene and methylation~gene~ represents the methylation level of a gene.

A risk score was assigned to each patient in TCGA dataset and the median risk score for all patients was calculated to divide patients into a low-risk group (risk score below the median value) and a high-risk group (risk score above the median value). To estimate the overall survival (OS) time and recurrence-free survival (RFS) time of the patients in the two risk groups, the Kaplan-Meier estimate ([@b21-ol-0-0-10931]) was used together with the Wilcoxon log rank test. The areas under the receiver operating characteristic (AUROC) curves were used to evaluate the prognostic ability of the risk scoring model and tested in the validation set.

Results
=======

### DM CpGs between samples with good and bad prognosis

With regard to the DNA methylation data of the TCGA set, 15654 methylated loci in CpGs were retained, according to the Illumina 450 K methylation platform. This set was comprised of 41 samples with bad prognosis and 72 samples with good prognosis. As shown in [Fig. 1A](#f1-ol-0-0-10931){ref-type="fig"}, a total of 742 DMGs (3.79×10^−7^ \<P-nominal \<6.84×10^−4^, 2.77×10^−5^ \<FDR \<0.05) were identified between the samples with good and bad prognosis. Kernel density plotting of log~2~FC showed that of the 742 DMGs, 289 were hypermethylated, whereas 453 were hypomethylated in the samples with good prognosis ([Fig. 1B](#f1-ol-0-0-10931){ref-type="fig"}). Two-way hierarchical clustering analysis based on the methylation levels of these DMGs revealed that the subjects in the TCGA set were clustered into two different groups ([Fig. 1C](#f1-ol-0-0-10931){ref-type="fig"}). Furthermore, out of the CpGs of the 742 identified DMGs, 447 were located in gene bodies, 155 in 5′ untranslated regions (UTRs), 98 in 3′UTRs and 42 in promoters. The top 20 DMGs were chosen according to their FDR value and shown in ascending order in [Table II](#tII-ol-0-0-10931){ref-type="table"}.

### LUAD-associated co-methylation modules

For the purpose of detecting LUAD-associated co-methylation modules, a weighted gene co-methylation network was constructed for the identified DMGs. As depicted in [Fig. 2A and B](#f2-ol-0-0-10931){ref-type="fig"}, the DMGs with significantly correlated methylation level (P\<0.05) were assigned into 13 methylation modules ([Table III](#tIII-ol-0-0-10931){ref-type="table"}). The DMGs without significant correlation in their methylation level were grouped into the grey module.

The enrichment of the DMGs in each module was analyzed using a hypergeometric-based test. Three modules with fold enrichment \>1 and P\<0.05 were identified as LUAD-associated methylation modules (black module, size=68; pink module, size=27; salmon module, size=26; [Fig. 2C](#f2-ol-0-0-10931){ref-type="fig"}). Moreover, GO enrichment analysis found that the total of 121 DMGs in the three modules were highly enriched in 16 biological processes, primarily associated with cell death, cytoskeleton organization and cell junction organization ([Table IV](#tIV-ol-0-0-10931){ref-type="table"}).

### Development and validation of a prognostic scoring model based on DMGs

The methylation levels of the 121 DMGs clustered in the three LUAD-associated modules were negatively correlated with their overall gene expression levels (PCC=−0.5008, P=1.618×10^−8^; [Fig. 3](#f3-ol-0-0-10931){ref-type="fig"}). Furthermore, the negative correlation between the methylation level of the individual gene and its gene expression level was observed in 94 genes, of which 58 DMGs were found to be significantly associated with survival via univariate Cox regression analysis (P\<0.05, [Table V](#tV-ol-0-0-10931){ref-type="table"}). Consequently, a LASSO Cox PH model was fitted with the methylation level of the 58 prognosis-associated DMGs. When the cross-validated likelihood (CVL) reached the maximal value of 1.537, the optimal λ value was −691.265. As a result, the most powerful prognostic panel of genes was selected, including *C20orf56*, BTG anti-proliferation factor 2 (*BTG2*), *C13orf16*, deoxyribonuclease 1 Like 1 (*DNASE1L1*), zinc finger DHHC-type containing 3 (*ZDHHC3*), FH2 domain containing 1 (*FHDC1*), ADP ribosylation factor 6 (*ARF6*), integrin subunit beta 3 (*ITGB3*) and intercellular adhesion molecule 4 (*ICAM4*) ([Table VI](#tVI-ol-0-0-10931){ref-type="table"}).

The association of the methylation level of the nine prognostic genes and survival was investigated. All samples in the TCGA set were dichotomized into hypermethylated group and hypomethylated group, based on the median methylation level of each prognostic gene, separately ([Fig. 4](#f4-ol-0-0-10931){ref-type="fig"}). For *C20orf56, BTG2, ZDHHC3, FHDC1* and *ICAM4*, the hypomethylated samples showed better prognosis compared with the hypermethylated samples (P\<0.05). By contrast, *DNASE1L1, ARF6, ITGB3* and *C13orf16* had significantly longer OS time in the hypermethylated samples relative to the hypomethylated samples.

The association between the gene expression level of the nine predictive genes and prognosis was also underscored. Specifically, all samples in the training set were divided into a high- and low-expression group, according to the median expression level of each gene, separately. High expression of *C20orf56, BTG2, ZDHHC3, FHDC1* and I*CAM4* showed significantly improved prognosis in comparison with low expression samples ([Fig. 5](#f5-ol-0-0-10931){ref-type="fig"}). Concerning *DNASE1L1, ARF6, ITGB3* and *C13orf16*, improved survival was reported in the low-expression samples relative to high-expression samples ([Fig. 5](#f5-ol-0-0-10931){ref-type="fig"}). For prognosis stratification, a prognostic scoring system was developed as follows: Risk score = (0.8529) × methylation~cg00933153~ + (0.9931) × methylation~cg01798157~ + (−0.5670) × methylation~cg01963754~ + (−0.1602) × methylation~cg04324559~ + (0.6870) × methylation~cg04432377~ + (1.0356) × methylation~cg07097184~ + (−0.9612) × Methylation~cg10156217~ + (−0.4113) × methylation~cg10753610~ + (0.4918) × methylation~cg21494776~.

The risk score was calculated for each individual patient in the TCGA set accordingly. All patients in the TCGA set were classified into a high- and low-risk group by risk score using the median risk score of all patients as the cut-off value. As shown in [Fig. 6A](#f6-ol-0-0-10931){ref-type="fig"}, low-risk patients had significantly longer OS time compared with the high-risk patients (P=8.992×10^−7^), with an AUC value of 0.966. The nine-gene methylation signature was also applied to predict the patients\' probability of recurrence in the training set. The low-risk patients had visibly longer RFS time in comparison with the high-risk patients, with an AUC value of 0.928 ([Fig. 6B](#f6-ol-0-0-10931){ref-type="fig"}). In order to test the capability of the nine-gene methylation signature, all samples in the validation set were classified by risk score into high- and low-risk groups. Similarly, low-risk patients had a dramatically longer RFS time relative to high-risk patients. The AUC value was 0.920 ([Fig. 6C](#f6-ol-0-0-10931){ref-type="fig"}), confirming the prognostic power of the nine-gene methylation signature.

Discussion
==========

LUAD is clinicopathologically and molecularly heterogeneous, making the prediction of patient outcome a necessity ([@b22-ol-0-0-10931],[@b23-ol-0-0-10931]). Gene silencing at the epigenetic level by DNA methylation was acknowledged as an important mechanism underlying tumorigenesis ([@b24-ol-0-0-10931]). The present study placed a special focus on DNA methylation alterations in LUAD and their implications for prognosis. A total of 742 DMGs were identified, showing significantly different methylations in CpGs between the samples designated as good and bad prognosis. There were three LUAD-associated DNA co-methylation modules mined by WGCNA. The 121 DMGs in the 3 modules were significantly associated with 16 GO terms. Notably, three GO terms were associated with cytoskeleton organization, two GO terms with transcription and four GO terms with cell apoptosis or death. These findings provided some insight into the underlying mechanisms of DNA methylation alterations in LUAD.

The present study identified a nine-gene methylation signature from the genes included in the three LUAD-associated DNA methylation modules. Moreover, risk score derived from the sum of each candidate methylation marker multiplied by the corresponding regression coefficient successfully classified patients into two risk groups, with significantly different OS or RFS time. The prognostic performance of this nine-gene signature was successfully verified for RFS time in the validation set. These findings indicate that the nine genes were valuable methylation markers for prognostic evaluation in LUAD patients.

The nine novel candidate methylation markers for prognosis prediction included *C20orf56, BTG2, C13orf16, DNASE1L1, ZDHHC3, FHDC1, ARF6, ITGB3* and *ICAM4*. Moreover, the present study found that hypomethylation/high expression of *ICAM4, ZDHHC3, C20orf56, BTG2* and *FHDC1* was associated with significantly improved survival outcome compared with hypermethylation/low expression. In contrast, hypermethylation/low expression of *DNASE1L1, ARF6, ITGB3* and *C13orf16* corresponded with significantly improved survival in comparison with when these genes were hypomethylated/highly expressed.

*BTG2* is involved in various biological activities, such as cell differentiation, proliferation and apoptosis, and has been acknowledged as a tumor suppressor in several types of cancer in humans, including laryngeal carcinoma, gastric cancer, clear cell renal cell carcinoma and breast carcinoma ([@b25-ol-0-0-10931]--[@b29-ol-0-0-10931]). More importantly, there is evidence that *BTG2* overexpression suppressed the growth and proliferation of lung cancer cells ([@b30-ol-0-0-10931]). It can be speculated that aberrant *BTG2* methylation participated in the regulation of genes involved in LUAD tumor growth. In addition, the present study implicated two possible functions for *BTG2*: Response to DNA damage stimulus and anterior/posterior pattern formation in LUAD. These findings offer useful information concerning the role of *BTG2* through the regulation of methylation in LUAD.

*ARF6* is a member of the human *ARF* gene family and plays a role in vesicular trafficking. Increasing evidence demonstrated an association between *ARF6* and tumor cell invasion ([@b31-ol-0-0-10931],[@b32-ol-0-0-10931]). Moreover, in the present study, GO analysis showed that *ARF6* was significantly implicated in the positive regulation of cytoskeleton organization, regulation of cellular component biogenesis, cell death, apoptosis and positive regulation of organelle organization. Thus, aberrant *ARF6* methylation may play a role in the regulation expression of genes associated with these biological processes in LUAD.

ITGB3, also known as CD61, is a protein encoded by *ITGB3* and participates in cell adhesion and signaling mediated by the cell surface ([@b33-ol-0-0-10931],[@b34-ol-0-0-10931]). The present study found that *ITGB3* was significantly enriched in cell junction organization in LUAD. Based on these observations, it can be inferred that alteration of *ITGB3* methylation exerted an effect on the expression of genes involved in cell junction organization, thus modulating cell adhesion and cell surface-mediated signaling. *ICAM4* is a member of the ICAMs family and is critical for inflammation and immune responses ([@b35-ol-0-0-10931]). DNASE1L1 is an enzyme encoded by *DNASE1L1*, a member of the human DNase family. To the best of our knowledge, there are few reports regarding the function of *ZDHHC3, C13orf16, C20orf56, FHDC1, ICAM4* and *DNASE1L1* in LUAD.

The limitations of the present study include minimal information on the OS time in the validation set, as other DNA methylation dataset of LUAD with survival information could not be located in NCBI GEO. Furthermore, only correlations between DNA methylation and the gene expression levels were investigated, based on data of LUAD downloaded from TCGA. Thus, protein expression of the nine novel candidate methylation markers for prognostic prediction should be also studied in the future. The aim of the present study was to provide novel prognostic DNA methylation biomarkers of LUAD, since the modern precise medicine for the treatment of LUAD required additional biomarkers and novel therapeutic targets of interest. However, the findings of the present study require validation in prospective clinical trials before the prognostic multigene methylation signature can be applied. Therefore, Chinese-population-based validation could be considered in the future.

In conclusion, the present study focused on the DNA methylation changes associated with LUAD and identified a prognostic nine-gene methylation signature for LUAD. The findings shed light on the DNA methylation landscape in LUAD and its implications on the development of optimized and individualized management of this condition.
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![Analysis of DMGs between samples with good and bad prognosis. (A) Volcano plot of effect size log~2~(FC) against -log~10~(FDR) of DMGs. Red spots represent DMGs with FDR\<0.05 (horizontal red dashed line) and \|log~2~FC\| \>0.1 (two vertical red dashed lines). (B) Kernel density plotting of log~2~(FC) displays 289 DMGs of hypermethylation (61.05%) and 453 DMGs of hypomethylation (38.95%). (C) Two-way hierarchical clustering analysis of the samples in the The Cancer Genome Atlas set, using a heatmap based on the methylation level of the DM CpGs. The color bar represents CpG methylation level (green to red, low to high level). FC, fold changes; FDR, false discovery rate; DMGs, differentially methylated genes.](ol-18-06-5831-g00){#f1-ol-0-0-10931}

![WGCNA methylation modules. (A) A hierarchical clustering dendrogram generated by WGCNA analysis. A total of 14 modules were identified and depicted in different colors. The colored row underneath shows the module assignment determined by the Dynamic Tree Cut. (B) The number of differentially methylated genes mapped to different modules. (C) Fold enrichment of each module. Fold enrichment represents enrichment of differentially methylated CpGs in each module. \*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001. WGCNA, weighted correlation network analysis.](ol-18-06-5831-g01){#f2-ol-0-0-10931}

![A scatter diagram for correlation analysis between the gene methylation and expression levels in the three lung adenocarcinoma-associated modules. Black dots represent the genes. The red line represents the trend line of the data points. Cor, Pearson\'s correlation coefficient.](ol-18-06-5831-g02){#f3-ol-0-0-10931}

![Kaplan-Meier curves of dichotomized patients, based on the methylation level of each gene in the training set. According to the methylation level of one gene, all patients in the training set were separated into a hypermethylation and a hypomethylation group.](ol-18-06-5831-g03){#f4-ol-0-0-10931}

![Kaplan-Meier curves showing patients, classified based on the expression level of each gene in the training set. Based on the gene expression level of one gene, all patients in the training set are classified into a high and low expression group.](ol-18-06-5831-g04){#f5-ol-0-0-10931}

![Kaplan-Meier curves (left panel) and ROC curves (right panel) demonstrating patients assigned to two risk groups, based on the nine-gene methylation signature in the (A and B) training set and the (C) validation set. (A) Overall survival time and (B) recurrence-free survival time of the high- and low-risk groups of the training set were estimated using Kaplan-Meier curves. The AUC of ROC reveals the capability of the nine-gene methylation signature to predict survival or recurrence. ROC, receiver operating characteristic; AUC, area under the curve.](ol-18-06-5831-g05){#f6-ol-0-0-10931}

###### 

Clinicopathological characteristics of patients in the training set and the validation set.

  Clinicopathological characteristics   Training set (n=425)   Validation set (n=155)
  ------------------------------------- ---------------------- ------------------------
  Age, years (mean ± SD)                65.12±10.04            65.11±10.85
  Sex, male/female                      198/227                76/79
  Death, dead/alive/-                   120/305                --
  OS time, months (mean ± SD)           22.13±28.39            --
  RFS time, months (mean ± SD)          18.802±26.34           54.68±45.62
  Recurrence, yes/no                    87/228                 68/87

SD, standard deviation; -, information unavailable; OS, overall survival; RFS, recurrence-free survival.

###### 

Top 20 significant differentially methylated genes.

  Methylated loci   Chromosome   Gene               Position    Location   β-good     β-bad      Effect     P~nominal~    FDR
  ----------------- ------------ ------------------ ----------- ---------- ---------- ---------- ---------- ------------- -------------
  cg21644316        3            QTRTD1             115260371   5′UTR      0.7249     0.8314     0.1978     3.79×10^−7^   2.77×10^−5^
  cg10753610        17           ITGB3              42690202    Body       0.2511     0.3604     0.5216     8.45×10^−7^   6.17×10^−5^
  cg02960016        3            HRH1               11167068    5′UTR      0.7498     0.6936     −0.1125    2.15×10^−6^   1.57×10^−4^
  cg12240358        15           HOMER2             81410528    Body       0.5326     0.4059     −0.3918    2.52×10^−6^   1.84×10^−4^
  cg07684796        10           DKK1               53744216    1stExon    0.1152     0.1554     0.4317     2.78×10^−6^   2.03×10^−4^
  cg18440692        10           FAM53B             126298025   3′UTR      0.4420     0.3205     −0.4636    3.17×10^−6^   2.31×10^−4^
  cg23894219        1            LOC441869          1346429     Body       0.5987     0.4876     −0.2961    4.50×10^−6^   3.28×10^−4^
  cg23581793        14           SCARNA13, SNHG10   95069529    Body       0.3519     0.4572     0.3778     5.54×10^−6^   4.05×10^−4^
  cg01531333        7            TMEM184A, MAFK     1548749     3′UTR      0.7444     0.8366     0.1685     5.97×10^−6^   4.36×10^−4^
  cg01289421        19           B3GNT3             17769247    5′UTR      0.6009     0.6740     0.1657     6.24×10^−6^   4.56×10^−4^
  cg07428439        17           LOC284023          7759563     Promoter   0.1277     0.1120     −0.1892    6.39×10^−6^   4.67×10^−4^
  cg01798157        1            BTG2               201543219   Promoter   0.5384     0.3961     −0.4427    7.28×10^−6^   5.32×10^−4^
  cg00259834        3            RFTN1              16528504    Promoter   0.3736     0.2582     −0.5332    7.45×10^−6^   5.44×10^−4^
  cg04481715        13           ATP4B              113351540   3′UTR      0.9121     0.8259     −0.1432    7.89×10^−6^   5.76×10^−4^
  cg26511108        10           COMMD3, BMI1       22648958    3′UTR      0.4687     0.5726     0.2886     8.86×10^−6^   6.47×10^−4^
  cg03366285        15           FSD2               81271781    5′UTR      0.724321   0.651058   −0.15384   9.07×10^−6^   6.63×10^−4^
  cg03087607        6            TCF21              134252361   body       0.427617   0.327662   −0.38411   9.66×10^−6^   7.06×10^−4^
  cg07097184        4            FHDC1              154119463   3′UTR      0.433799   0.359003   −0.27303   1.17×10^−5^   8.58×10^−4^
  cg02538597        12           ARPC3              109372526   Promoter   0.099173   0.090652   −0.12961   1.35×10^−5^   9.89×10^−4^
  cg24272980        3            CIDECP             10040206    Body       0.752599   0.816553   0.117666   1.36×10^−5^   9.92×10^−4^

UTR, untranslated region; FDR, false discovery rate.

###### 

Methylation modules from weighted correlation network analysis.

  Module color   Count of CpGs   Correlation efficient   P~corr~   Count of DM CpGs   Enrichment fold (95% CI)   P~hyper~
  -------------- --------------- ----------------------- --------- ------------------ -------------------------- ----------
  Black          468             0.502                   0.0024    68                 2.818 (2.106--3.728)       \<0.0001
  Blue           368             0.609                   0.0033    22                 1.159 (0.709--1.811)       0.4730
  Brown          410             0.488                   0.0047    10                 0.473 (0.223--0.889)       0.0176
  Green          302             0.495                   0.0027    18                 1.156 (0.668--1.886)       0.5110
  Yellow         228             0.486                   0.0023    8                  0.681 (0.288--1.379)       0.3560
  Grey           3363            0.407                   0.6550    117                0.674 (0.541--0.837)       0.0002
  Magenta        341             0.532                   0.0007    17                 0.967 (0.550--1.594)       0.9680
  Pink           299             0.469                   0.0005    27                 1.752 (1.119--2.644)       0.0095
  Purple         194             0.517                   0.0068    10                 0.999 (0.468--1.901)       1.0000
  Red            127             0.539                   0.0005    1                  0.153 (0.038--0.872)       0.0214
  Salmon         138             0.428                   0.0039    26                 3.653 (2.275--5.673)       \<0.0001
  Tan            127             0.471                   0.0045    8                  1.222 (0.512--2.509)       0.5450
  Turquoise      343             0.811                   0.0029    15                 0.848 (0.465--1.439)       0.6160
  Yellow         256             0.518                   0.0007    12                 0.909 (0.459--1.637)       0.8850

Count of CpGs, the number of CpGs included in one module; DM, differentially methylated; count of DM CpGs, the number of DM CpGs mapped to one module; P~corr~, P-value for correlation coefficient; P~hyper,~ P-value for enrichment analysis; CI, confidential interval.

###### 

Significant GO terms for the three LUAD-associated modules.

  GO term                                                       Count of genes   Fold enrichment   P-value
  ------------------------------------------------------------- ---------------- ----------------- ---------
  Cytoskeleton organization                                     8                2.821             0.0110
  Response to DNA damage stimulus                               7                2.885             0.0165
  Spindle organization                                          3                10.248            0.0169
  Positive regulation of cytoskeleton organization              3                10.248            0.0169
  Regulation of transcription from RNA polymerase II promoter   10               2.115             0.0218
  Cell junction organization                                    3                8.091             0.0260
  Anterior/posterior pattern formation                          4                4.392             0.0307
  Regulation of cellular component biogenesis                   4                4.330             0.0318
  Microtubule cytoskeleton organization                         4                4.183             0.0345
  Positive regulation of transcription, DNA-dependent           7                2.256             0.0433
  Positive regulation of RNA metabolic process                  7                2.237             0.0446
  Cell death                                                    9                1.924             0.0454
  Apoptosis                                                     8                2.043             0.0462
  Death                                                         9                1.911             0.0468
  Programmed cell death                                         8                2.013             0.0490
  Positive regulation of organelle organization                 3                5.556             0.0498

GO, Gene Ontology; LUAD: lung adenocarcinoma; Count of genes, the number of genes significantly enriched in one GO term.

###### 

Genes associated with survival according to Cox regression analysis.

  ID           Gene        P-value
  ------------ ----------- ------------
  cg03395898   TGFB3       6.0×10^−5^
  cg01798157   BTG2        4.2×10^−4^
  cg07097184   FHDC1       5.1×10^−4^
  cg02334643   DHX40       8.4×10^−4^
  cg05003322   COL16A1     8.6×10^−4^
  cg27500918   FLYWCH2     9.1×10^−4^
  cg00933153   C20orf56    1.0×10^−3^
  cg20541456   CYFIP2      1.1×10^−4^
  cg05898928   YPEL1       1.2×10^−4^
  cg16194253   C14orf21    1.5×10^−4^
  cg21494776   ICAM4       1.6×10^−4^
  cg11013977   QRICH1      1.7×10^−4^
  cg06620210   AP1M1       2.1×10^−4^
  cg02016545   MICA        2.3×10^−4^
  cg03595580   TECPR1      2.5×10^−4^
  cg18050194   SEC22C      4.0×10^−3^
  cg08517562   PTPN1       5.6×10^−4^
  cg02156071   C10orf84    5.7×10^−4^
  cg06877599   SUPT5H      5.7×10^−4^
  cg04902921   EDEM3       6.3×10^−4^
  cg16740905   SEC1        6.9×10^−4^
  cg04432377   ZDHHC3      7.1×10^−4^
  cg10753610   ITGB3       7.9×10^−4^
  cg05714082   POLR1A      8.5×10^−4^
  cg04446303   TFAP4       9.4×10^−4^
  cg02282317   AATF        0.011
  cg08100565   SLC25A36    0.011
  cg01889020   MEGF11      0.014
  cg02181309   MRPL52      0.014
  cg01498883   SNRPB       0.014
  cg06677352   STAG3L3     0.014
  cg24122247   CIDECP      0.015
  cg24135606   PFN1        0.016
  cg24612420   ACLY        0.017
  cg19759282   GPR155      0.017
  cg13939431   MEAF6       0.017
  cg01963754   C13orf16    0.018
  cg04324559   DNASE1L1    0.019
  cg24951800   MEF2A       0.019
  cg00567190   C1orf97     0.020
  cg12811419   TMEM214     0.024
  cg00399374   CHMP4C      0.025
  cg01779512   IFT88       0.027
  cg16931807   KIAA0195    0.032
  cg15599146   ZDHHC14     0.033
  cg07459266   RNF213      0.034
  cg08125503   PIGL        0.035
  cg07057042   RAB5A       0.035
  cg21994174   ETFB        0.036
  cg06421633   LUC7L3      0.036
  cg03270167   RAMP1       0.037
  cg05006947   SLC38A7     0.040
  cg10156217   ARF6        0.042
  cg07097417   LPGAT1      0.042
  cg02146453   PROSC       0.043
  cg17286258   SF3B1       0.043
  cg18085070   PSRC1       0.044
  cg27229100   C20orf199   0.046

###### 

A panel of nine differentially methylated genes predictive of prognosis.

  ID           Gene       Chromosome   Position    Location   Coefficient   Hazard ratio   P-value
  ------------ ---------- ------------ ----------- ---------- ------------- -------------- ---------
  cg00933153   C20orf56   20           22498129    Body       0.8529        3.177          0.0010
  cg01798157   BTG2       1            201543218   Promoter   0.9931        2.606          0.0004
  cg01963754   C13orf16   13           110775249   Body       −0.5670       0.499          0.0180
  cg04324559   DNASE1L1   X            153290455   5′UTR      −0.1602       0.712          0.0190
  cg04432377   ZDHHC3     3            44992301    Promoter   0.6870        2.894          0.0071
  cg07097184   FHDC1      4            154119462   3′UTR      1.0356        5.175          0.0005
  cg10156217   ARF6       14           49432104    Promoter   −0.9612       0.260          0.0420
  cg10753610   ITGB3      17           42690201    Body       −0.4113       0.489          0.0079
  cg21494776   ICAM4      19           10258780    Body       0.4918        2.065          0.0016

[^1]: Contributed equally
